
Foresight Diagnostics was founded by four Stanford University physicians and scientists who sought to develop high-performing circulating tumor DNA (ctDNA) assays by improving the limits of detection through innovative techniques and enhanced bioinformatics. Our product, Foresight CLARITY™, utilizes a proprietary and patented phased variant (PV) detection method to improve the accuracy of ctDNA tests and minimal residual disease (MRD) measurement. Foresight Diagnostics was acquired by Natera in December 2025 and operates a CLIA laboratory in Boulder, Colorado.
Annual Revenue$50M to $100M
Estimated OwnershipPublicBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.